Biomaterial Database

Successful Treatment of Cutaneous Small Vessel Vasculitis With Leflunomide. 2017

Julia D Stiegler, and Naveed Sami

Department of Dermatology, University of Alabama School of Medicine, Birmingham, Alabama.

UI	MeSH Term	Description	Entries
D007166	Immunosuppressive Agents	Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.	Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D005260	Female		Females
D005500	Follow-Up Studies	Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.	Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077339	Leflunomide	An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.	Arava,HWA 486,HWA-486,N-(4-Trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide,SU101,HWA486
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D001706	Biopsy	Removal and pathologic examination of specimens from the living body.	Biopsies
D012867	Skin	The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
D018366	Vasculitis, Leukocytoclastic, Cutaneous	Disorder characterized by a vasculitic syndrome associated with exposure to an antigen such as a drug, infectious agent, or other foreign or endogenous substance. Its pathophysiology includes immune complex deposition and a wide range of skin lesions. Hypersensitivity or allergy is present in some but not all cases.	Angiitis, Hypersensitivity,Cutaneous Leukocytoclastic Vasculitis,Hypersensitivity Angiitis,Hypersensitivity Vasculitis,Vasculitis, Hypersensitivity,Allergic Cutaneous Angiitis,Allergic Cutaneous Vasculitis,Angiitis, Allergic Cutaneous,Cutaneous Allergic Vasculitis,Cutaneous Leukocytoclastic Angiitis,Vasculitis, Allergic Cutaneous,Allergic Cutaneous Angiitides,Allergic Cutaneous Vasculitides,Allergic Vasculitides, Cutaneous,Allergic Vasculitis, Cutaneous,Angiitides, Allergic Cutaneous,Angiitides, Cutaneous Leukocytoclastic,Angiitides, Hypersensitivity,Angiitis, Cutaneous Leukocytoclastic,Cutaneous Allergic Vasculitides,Cutaneous Angiitides, Allergic,Cutaneous Angiitis, Allergic,Cutaneous Leukocytoclastic Angiitides,Cutaneous Leukocytoclastic Vasculitides,Cutaneous Vasculitides, Allergic,Cutaneous Vasculitis, Allergic,Hypersensitivity Angiitides,Hypersensitivity Vasculitides,Leukocytoclastic Angiitides, Cutaneous,Leukocytoclastic Angiitis, Cutaneous,Leukocytoclastic Vasculitides, Cutaneous,Leukocytoclastic Vasculitis, Cutaneous,Vasculitides, Allergic Cutaneous,Vasculitides, Cutaneous Allergic,Vasculitides, Cutaneous Leukocytoclastic,Vasculitides, Hypersensitivity,Vasculitis, Cutaneous Allergic,Vasculitis, Cutaneous Leukocytoclastic